What is the Piramal Pharma Ltd share price today?

The share price of NSE:PPLPHARMA-EQ on 01 Oct 2026 (as of 15:04:35 IST) is ₹197.23.

What is the NSE:PPLPHARMA-EQ 52 week high low price?

Over the past 52 weeks (as of 01 Oct 2026), the NSE:PPLPHARMA-EQ 52 week high low range shows a high of ₹231.93 and a low of ₹132.3.

What is the Piramal Pharma Ltd market cap?

As on 01 Oct 2026, Piramal Pharma Ltd market cap is ₹274657000000.

What is the shareholding pattern of Piramal Pharma Ltd Stock?

The shareholding pattern of Piramal Pharma Ltd, as of last reported-on 30 Jun 2026 is: Promoters: 34.8% Foreign Institutional Investors (FII): 12.51% Domestic Institutional Investors (DII): 1.39% Mutual Funds: 13.18% Retail & Others: 38.12% This demonstrates an outstanding distribution of ownership.

What are the PE and PB ratios of Piramal Pharma Ltd?

The Price-to-Earnings (PE) ratio of Piramal Pharma Ltd is 0, and the Price-to-Book (PB) ratio is 2.2385, as on 01 Oct 2026.

Piramal Pharma Share Price

200.52+5.63 (+2.89%)

+1.03% past 1 Year

Prices are delayed by 1 hour. Login or Sign Up for live updates.Prices are delayed by 1 hour. Login or Sign Up for live updates.

1 Day

+2.89%

1 Week

+1.29%

1 Month

-6.40%

3 Month

+19.28%

6 Month

+40.27%

YTD

+16.44%

1 Year

+1.03%

5 Year

10 Year

Max

+2.67%

YTD

10Y

MAX

Prices are delayed by 1 hour. Login or Sign Up for live updates.Prices are delayed by 1 hour. Login or Sign Up for live updates.

Price Analysis

1 Day

1 Week

1 Month

3 Months

6 Months

1 Year

Low

193.75

166.25

140.96

132.30

High

201.20

201.65

231.93

About

Piramal Pharma (PPL) is one of the India’s largest Pharmaceutical Company. PPL offers a portfolio of differentiated products and services through its global development and manufacturing facilities and a global Read more

Pharmaceuticals & Drugs

Smallcap

Stock Analysis (SWOT)

StrengthsWeaknessesOpportunitiesThreats

1. Premium insight available after login

2. Sign in to view full SWOT analysis

3. Unlock strengths, weaknesses, opportunities & threats

QVT

Quality

0/100-

Valuation

0/100-

Technical

0/100-

Peer Stocks

1 week

1 month

1 year

Name

SUNPHARMANSE

DIVISLABNSE

TORNTPHARMNSE

ZYDUSLIFENSE

CIPLANSE

LAURUSLABSNSE

MANKINDNSE

DRREDDYNSE

AUROPHARMANSE

LUPINNSE

PPLPHARMANSE

LTP

1W Low

1W High

Market cap (₹)

1804.1+3.1 (0.17%)

1768

1804.10

4,27,562Cr

9550+301 (3.25%)

9113.50

9557.50

2,44,572Cr

4772+4.7 (0.10%)

4702.50

4795

1,80,871Cr

1159.5+13.8 (1.20%)

1128.10

1164.80

1,13,566Cr

1340.2-3.8 (-0.28%)

1321

1344.90

1,07,770Cr

2050+66 (3.33%)

1955.10

2054.90

1,06,117Cr

2500-35 (-1.38%)

2464.50

2539.30

1,02,433Cr

1208+1.8 (0.15%)

1189

1212.70

1,00,829Cr

1692.8+16 (0.95%)

1663.10

1696

96,088Cr

2029.3-1.9 (-0.09%)

1996.30

2031.40

91,915Cr

200.52+2.55 (1.29%)

193.75

201.65

25,948Cr

Piramal Pharma Share Price

200.52+5.63 (+2.89%)

+1.03% past 1 Year

Financial overview

Compounded Sales Growth

10 years-

5 years7%

3 years8%

Last year-3%

Compounded Profit Growth

10 years-

5 years-

3 years-

Last year-458%

Stock Price CAGR

10 years-

5 years-

3 years25%

1 year-2%

Return on Equity

10 years3%

5 years0%

3 years-1%

Last year-4%

CAGR%

Sales

Profits

Returns

ROE

10Y	5Y	3Y	TTM
-	7%	8%	-3%
-	-	-	-458%
-	-	25%	-2%
3%	0%	-1%	-4%

Peer Comparison

Symbol

SUNPHARMA

DIVISLAB

TORNTPHARM

ZYDUSLIFE

CIPLA

LAURUSLABS

MANKIND

DRREDDY

AUROPHARMA

LUPIN

PPLPHARMA

Price	M.Cap (₹)	PE Ratio	EPS (₹)	EV/EBITDA	Annual PAT
1,804.1	₹427562 Cr	35.35	12.07	62.82	₹11479 Cr
9,550	₹244572 Cr	83.61	34.04	128.41	₹2568 Cr
4,772	₹180871 Cr	82.93	16.72	97.06	₹2163 Cr
1,159.5	₹113566 Cr	25.16	9.42	62.53	₹5040 Cr
1,340.2	₹107770 Cr	31.97	9.77	57.87	₹3879 Cr
2,050	₹106117 Cr	97.06	6.8	29.25	₹889 Cr
2,500	₹102433 Cr	50.15	13.75	71.08	₹1913 Cr
1,208	₹100829 Cr	31.29	5.32	63.99	₹4196 Cr
1,692.8	₹96088 Cr	25.88	17.95	96.84	₹3505 Cr
2,029.3	₹91915 Cr	16.62	30.95	154.35	₹5333 Cr
200.52	₹25948 Cr	—	-0.52	4.09	-₹326 Cr

Profit & Loss

Consolidated

Standalone

Quarterly

Yearly

₹

Name

Net Revenue

Other Income

Total Revenue

Total Expenditure

Operating Profit

Interest Expense

PBT

Net Profit

Jun 2026	Mar 2026	Dec 2025	Sep 2025	Jun 2025	Mar 2025	Dec 2024	Sep 2024	Jun 2024	Mar 2024	Dec 2023	Sep 2023	Jun 2023	Mar 2023	Dec 2022	Sep 2022	Jun 2022	Mar 2022	Dec 2021	Sep 2021
₹2270 Cr	₹2752 Cr	₹2140 Cr	₹2044 Cr	₹1934 Cr	₹2754 Cr	₹2204 Cr	₹2242 Cr	₹1951 Cr	₹2552 Cr	₹1959 Cr	₹1911 Cr	₹1749 Cr	₹2164 Cr	₹1716 Cr	₹1720 Cr	₹1482 Cr	₹2131 Cr	₹1539 Cr	₹1578 Cr
₹89 Cr	₹46 Cr	₹43 Cr	₹66 Cr	₹58 Cr	₹42 Cr	₹12 Cr	₹61 Cr	₹20 Cr	₹26 Cr	₹62 Cr	₹49 Cr	₹38 Cr	₹25 Cr	₹83 Cr	₹46 Cr	₹72 Cr	₹78 Cr	₹161 Cr	₹18 Cr
₹2359 Cr	₹2798 Cr	₹2183 Cr	₹2109 Cr	₹1992 Cr	₹2796 Cr	₹2216 Cr	₹2303 Cr	₹1971 Cr	₹2579 Cr	₹2020 Cr	₹1961 Cr	₹1787 Cr	₹2188 Cr	₹1799 Cr	₹1766 Cr	₹1554 Cr	₹2210 Cr	₹1700 Cr	₹1595 Cr
₹2298 Cr	₹2510 Cr	₹2157 Cr	₹2088 Cr	₹2024 Cr	₹2436 Cr	₹2063 Cr	₹2092 Cr	₹1931 Cr	₹2219 Cr	₹1877 Cr	₹1830 Cr	₹1790 Cr	₹1997 Cr	₹1793 Cr	₹1714 Cr	₹1627 Cr	₹1899 Cr	₹1461 Cr	₹1519 Cr
₹285 Cr	₹507 Cr	₹239 Cr	₹224 Cr	₹165 Cr	₹603 Cr	₹350 Cr	₹403 Cr	₹224 Cr	₹556 Cr	₹330 Cr	₹315 Cr	₹171 Cr	₹376 Cr	₹170 Cr	₹219 Cr	₹89 Cr	₹476 Cr	₹386 Cr	₹214 Cr
₹88 Cr	₹83 Cr	₹89 Cr	₹82 Cr	₹86 Cr	₹104 Cr	₹103 Cr	₹108 Cr	₹107 Cr	₹114 Cr	₹106 Cr	₹110 Cr	₹119 Cr	₹104 Cr	₹95 Cr	₹83 Cr	₹62 Cr	₹57 Cr	₹50 Cr	₹49 Cr
-₹27 Cr	₹29 Cr	-₹104 Cr	-₹61 Cr	-₹98 Cr	₹257 Cr	₹50 Cr	₹103 Cr	-₹67 Cr	₹215 Cr	₹5 Cr	₹20 Cr	-₹122 Cr	₹87 Cr	-₹89 Cr	-₹37 Cr	-₹135 Cr	₹254 Cr	₹189 Cr	₹27 Cr
-₹89 Cr	-₹22 Cr	-₹146 Cr	-₹114 Cr	-₹100 Cr	₹137 Cr	-₹13 Cr	₹5 Cr	-₹111 Cr	₹89 Cr	-₹4 Cr	-₹14 Cr	-₹113 Cr	₹42 Cr	-₹106 Cr	-₹48 Cr	-₹129 Cr	₹185 Cr	₹154 Cr	₹20 Cr

Balance Sheet

Consolidated

Standalone

₹

Name

Equity And Liabilities

Share Capital

Share Warrants & Outstandings

Total Reserves

Reserve excluding Revaluation Reserve

Shareholder's Funds

Secured Loans

Deferred Tax Assets / Liabilities

Other Long Term Liabilities

Long Term Provisions

Total Non-Current Liabilities

Current Liabilities

Trade Payables

Other Current Liabilities

Short Term Borrowings

Short Term Provisions

Total Current Liabilities

Total Liabilities

Contingent Liabilities

Total Debt

Assets

Gross Block

Less Accumulated Depreciation

Less Impairment of Assets

Net Block

Capital Work in Progress

Non Current Investments

Long Term Investment

Long Term Loans & Advances

Other Non Current Assets

Total Non-Current Assets

Current Assets Loans & Advances

Currents Investments

Inventories

Sundry Debtors

Cash and Bank

Other Current Assets

Short Term Loans and Advances

Total Current Assets

Net Current Assets (Including Current Investments)

Total Assets

Book Value

Adjusted Book Value

Mar 2026	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
—	—	—	—	—	—
₹1327 Cr	₹1324 Cr	₹1323 Cr	₹1193 Cr	₹1186 Cr	₹995 Cr
₹73 Cr	₹62 Cr	₹27 Cr	₹0	₹0	₹10 L
₹6763 Cr	₹6739 Cr	₹6561 Cr	₹5580 Cr	₹5511 Cr	₹4610 Cr
₹6763 Cr	₹6739 Cr	₹6561 Cr	₹5580 Cr	₹5511 Cr	₹4610 Cr
₹8163 Cr	₹8125 Cr	₹7911 Cr	₹6774 Cr	₹6697 Cr	₹5605 Cr
₹4300 Cr	₹3214 Cr	₹2484 Cr	₹3384 Cr	₹2622 Cr	₹2339 Cr
-₹157 Cr	-₹145 Cr	-₹157 Cr	-₹130 Cr	-₹105 Cr	-₹22 Cr
₹292 Cr	₹275 Cr	₹286 Cr	₹282 Cr	₹240 Cr	₹236 Cr
₹94 Cr	₹49 Cr	₹32 Cr	₹276 Cr	₹145 Cr	₹7 Cr
₹4529 Cr	₹3393 Cr	₹2645 Cr	₹3812 Cr	₹2903 Cr	₹2560 Cr
—	—	—	—	—	—
₹2479 Cr	₹1534 Cr	₹1538 Cr	₹1193 Cr	₹1026 Cr	₹918 Cr
₹1479 Cr	₹1185 Cr	₹1576 Cr	₹1305 Cr	₹1243 Cr	₹1141 Cr
₹748 Cr	₹995 Cr	₹1171 Cr	₹1302 Cr	₹659 Cr	₹361 Cr
₹169 Cr	₹137 Cr	₹84 Cr	₹51 Cr	₹190 Cr	₹172 Cr
₹4875 Cr	₹3851 Cr	₹4369 Cr	₹3851 Cr	₹3118 Cr	₹2591 Cr
₹17567 Cr	₹15369 Cr	₹14925 Cr	₹14437 Cr	₹12717 Cr	₹10756 Cr
₹96 Cr	₹100 Cr	₹61 Cr	₹57 Cr	₹45 Cr	₹30 Cr
₹5495 Cr	₹4720 Cr	₹4559 Cr	₹5505 Cr	₹4023 Cr	₹2910 Cr
—	—	—	—	—	—
₹14905 Cr	₹13118 Cr	₹12138 Cr	₹10842 Cr	₹9510 Cr	₹8173 Cr
₹6214 Cr	₹4984 Cr	₹4148 Cr	₹3374 Cr	₹2631 Cr	₹2068 Cr
₹7 Cr	₹0	₹0	₹0	₹0	₹0
₹8684 Cr	₹8133 Cr	₹7990 Cr	₹7469 Cr	₹6879 Cr	₹6105 Cr
₹799 Cr	₹489 Cr	₹566 Cr	₹853 Cr	₹673 Cr	₹400 Cr
₹305 Cr	₹271 Cr	₹240 Cr	₹212 Cr	₹217 Cr	₹123 Cr
₹305 Cr	₹271 Cr	₹240 Cr	₹212 Cr	₹217 Cr	₹123 Cr
₹155 Cr	₹91 Cr	₹115 Cr	₹494 Cr	₹297 Cr	₹152 Cr
₹15 Cr	₹15 Cr	₹0	₹4 L	₹4 L	₹4 L
₹10259 Cr	₹9487 Cr	₹9461 Cr	₹9593 Cr	₹8565 Cr	₹7007 Cr
—	—	—	—	—	—
₹132 Cr	₹20 Cr	₹145 Cr	₹427 Cr	₹50 Cr	₹0
₹3064 Cr	₹2313 Cr	₹2176 Cr	₹1681 Cr	₹1389 Cr	₹1232 Cr
₹2158 Cr	₹2350 Cr	₹2134 Cr	₹1799 Cr	₹1785 Cr	₹1575 Cr
₹1224 Cr	₹501 Cr	₹483 Cr	₹308 Cr	₹329 Cr	₹406 Cr
₹145 Cr	₹135 Cr	₹82 Cr	₹140 Cr	₹94 Cr	₹141 Cr
₹586 Cr	₹563 Cr	₹445 Cr	₹488 Cr	₹505 Cr	₹396 Cr
₹7308 Cr	₹5881 Cr	₹5464 Cr	₹4843 Cr	₹4152 Cr	₹3749 Cr
₹2433 Cr	₹2031 Cr	₹1095 Cr	₹992 Cr	₹1034 Cr	₹1158 Cr
₹17567 Cr	₹15369 Cr	₹14925 Cr	₹14437 Cr	₹12717 Cr	₹10756 Cr
₹61	₹61	₹60	₹57	₹56	₹56
₹61	₹61	₹60	₹55	₹55	₹55

Cash Flow

Consolidated

Standalone

₹

Name

Profit Before Tax

Adjustment

Changes In working Capital

Cash Flow after changes in Working Capital

Cash Flow from Operating Activities

Cash Flow from Investing Activities

Cash Flow from Financing Activitie

Net Cash Inflow / Outflow

Opening Cash & Cash Equivalents

Cash & Cash Equivalent on Amalgamation / Take over / Merger

Cash & Cash Equivalent of Subsidiaries under liquidations

Effect of Foreign Exchange Fluctuations

Closing Cash & Cash Equivalent

Mar 2026	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
-₹233 Cr	₹342 Cr	₹120 Cr	-₹161 Cr	₹441 Cr	₹884 Cr
₹1569 Cr	₹1373 Cr	₹1276 Cr	₹1136 Cr	₹787 Cr	₹478 Cr
₹527 Cr	-₹488 Cr	-₹234 Cr	-₹302 Cr	-₹292 Cr	-₹620 Cr
₹1863 Cr	₹1227 Cr	₹1161 Cr	₹673 Cr	₹936 Cr	₹742 Cr
₹1653 Cr	₹892 Cr	₹1005 Cr	₹484 Cr	₹766 Cr	₹598 Cr
-₹826 Cr	-₹477 Cr	-₹434 Cr	-₹1339 Cr	-₹1812 Cr	-₹4480 Cr
-₹39 Cr	-₹441 Cr	-₹422 Cr	₹818 Cr	₹794 Cr	₹3977 Cr
₹788 Cr	-₹26 Cr	₹148 Cr	-₹37 Cr	-₹251 Cr	₹94 Cr
₹182 Cr	₹219 Cr	₹53 Cr	₹85 Cr	₹262 Cr	₹152 Cr
₹0	₹0	₹0	₹0	₹77 Cr	₹0
₹0	₹0	₹0	₹0	₹0	₹11 Cr
₹6 Cr	-₹11 Cr	₹18 Cr	₹5 Cr	-₹2 Cr	₹4 Cr
₹976 Cr	₹182 Cr	₹219 Cr	₹53 Cr	₹85 Cr	₹262 Cr

Fundamental Ratios

Consolidated

Standalone

No results found

Piramal Pharma Share Price

200.52+5.63 (+2.89%)

+1.03% past 1 Year

Shareholding summary

Promoters

34.8%

FII

12.51%

DII

1.39%

13.18%

Others

38.12%

Promoters

FII

DII

Others

Quarterly

Yearly

Shareholding Pattern

Quarterly

Yearly

Name

Promoters

FII

DII - Others

DII - MFs

Retail & Others

Jun 2026	Mar 2026	Dec 2025	Sep 2025	Jun 2025	Mar 2025
34.80%	34.86%	34.86%	34.86%	34.86%	34.95%
12.51%	30.17%	29.66%	30.27%	30.86%	31.49%
1.39%	1.49%	1.66%	1.78%	1.93%	2.05%
13.18%	14.12%	14.03%	13.11%	12.32%	12.73%
38.12%	19.36%	19.79%	19.98%	20.03%	18.78%

Bulk & block deals

Name

Graviton Research Capital Llp

East Bridge Capital Master Fund I Limited

East Bridge Capital Master Fund Limited

East Bridge Capital Master Fund I Limited

East Bridge Capital Master Fund Limited

The Vanguard Group Inc Ac Vanguard Total International Stock Index Fund

Caisse De Depot Et Placement Du Quebec

Ishares Core Msci Emerging Markets Etf

Ishares Core Emerging Markets Mauritius Co

Deal Date	Action	Deal Value	Deal Price	Qty Traded	Deal Type	%Stake Traded	Exchange
20 Feb 2025	Purchase	150.65 Cr	₹219.70	68.57 L	Bulk	0.515039	NSE
20 Feb 2025	Sell	150.77 Cr	₹219.88	68.57 L	Bulk	0.515039	NSE
31 Oct 2023	Purchase	345.85 Cr	₹102.80	3.36 Cr	Bulk	2.526995	BSE
31 Oct 2023	Sell	345.85 Cr	₹102.80	3.36 Cr	Bulk	2.526995	BSE
31 Oct 2023	Purchase	345.85 Cr	₹102.80	3.36 Cr	Block	2.526995	BSE
31 Oct 2023	Sell	345.85 Cr	₹102.80	3.36 Cr	Block	2.526995	BSE
16 Jun 2023	Purchase	58.75 Cr	₹94.71	62.03 L	Bulk	0.465912	NSE
16 Jun 2023	Sell	99.87 Cr	₹94.48	1.06 Cr	Bulk	0.793967	NSE
03 Nov 2022	Purchase	67.63 Cr	₹166.95	40.51 L	Block	0.304256	BSE
03 Nov 2022	Sell	67.63 Cr	₹166.95	40.51 L	Block	0.304256	BSE

Insider trading & SAST

Client name

Hdfc Mutual Fund

East Bridge Capital Master Fund I Ltd & East Bridge Capital Master Fund

Hdfc Mutual Fund

Ajay G Piramal & Others

Caisse De Depot Et Placement Du Quebec

Deutsche Bank Ag, Singapore Branch, Dbx Advisors Llc

Deutsche Bank Ag, Singapore Branch , Dbx Advisors Llc

Reported on	Client category	Action	%Stake traded	Holding % post deal	Deal price	Qty traded	Deal period	Deal mode	Post transaction holding	Insider/SAST	Regulation type	Security type
06 Aug 2026	Other	Disposal	2	7.01	—	2.67 Cr	14 Jul 2026	Market	9,33,93,655	SAST	29(2)	—
10 Jul 2025	Other	Acquisition	1.99	9.03	—	2.65 Cr	26 Jun 2025	Market	12,00,82,126	SAST	29(2)	—
09 Oct 2024	Other	Disposal	0.17	3.6	—	21.99 L	06 Sep 2024	Market	4,77,72,918	SAST	29(2)	—
02 Aug 2024	Other	Acquisition	2.06	7.06	—	2.73 Cr	29 Jul 2024	Market	9,35,33,550	SAST	29(2)	—
19 Mar 2024	Other	Acquisition	0.06	5.01	—	8.21 L	14 Mar 2024	Market	6,62,51,434	SAST	29(1)	—
06 Sep 2023	Promoter	Acquisition	37.2	35.02	—	4.82 Cr	23 Aug 2023	Rights Issue	46,33,31,304	SAST	29(2)	—
06 Sep 2023	Promoter	Acquisition	37.2	35.02	—	4.82 Cr	23 Aug 2023	Rights Issue	46,33,31,304	SAST	29(1)	—
06 Jun 2023	Other	Disposal	0.17	3.54	—	20.14 L	29 May 2023	Market	4,22,97,333	SAST	29(2)	—
17 Nov 2022	Other	Acquisition	20	20	—	23.87 Cr	19 Oct 2022	Encumbrance Shares	23,86,63,700	SAST	29(1)	—
17 Nov 2022	Other	Acquisition	—	—	—	46 K	19 Oct 2022	Encumbrance Shares	45,996	SAST	29(1)	—

Piramal Pharma Share Price

Price Analysis

Share Price Live Stats

Share Market Cap & Key Ratios Overview

About

Stock Analysis (SWOT)

QVT

Peer Stocks

Piramal Pharma Share Price

Piramal Pharma Share Price

Financial overview

Compounded Sales Growth

Compounded Profit Growth

Stock Price CAGR

Return on Equity

Peer Comparison

Profit & Loss

Balance Sheet

Cash Flow

Fundamental Ratios

Piramal Pharma Share Price

Piramal Pharma Share Price

Oscillators

Moving averages

Piramal Pharma Share Price

Shareholding summary

Shareholding Pattern

Bulk & block deals

Insider trading & SAST

Piramal Pharma Share Price

Corporate Actions

Company details

Piramal Pharma Share Price

Corporate filings & documents

Announcements

Annual reports

Concalls & investor presentations

Piramal Pharma Share Price

News

Piramal Pharma Bayer Sales Arrangement Ends December 31 2026 Without Renewal

Piramal Pharma UK Morpeth plant gets seven US FDA observations post inspection

Piramal Pharma NSE block trade of Rs 15.12 crores at Rs 223.51

Piramal Pharma raises stake in Yapan Bio, makes it a subsidiary

Piramal Pharma, Carlyle selldown cancellation reported by IIFL

Piramal Pharma sees Rs 29.81 crores NSE block trade at Rs 205.01

Piramal Pharma Restarts Ahmedabad Operations After Flood Disruption

Goldman Sachs reiterates Buy on Piramal Pharma with Rs 250 target

Piramal Pharma maintains steady capex guidance with Lexington project on schedule

Piramal Pharma highlights elevated effective tax rate during current fiscal scale-up

Piramal Pharma reiterates full-year guidance for complex hospital generics

Piramal Pharma maintains existing guidance, potential update after September quarter

Piramal Pharma management reiterates full-year CDMO revenue guidance on concall

Piramal Pharma reiterates FY30 target of 25 percent EBITDA margin

Piramal Pharma maintains FY27 capex guidance at Rs 12-13.5 crores

Piramal Pharma guides for EBITDA margin expansion on overseas growth visibility

Piramal Pharma guides elevated FY27 tax rate before gradual normalization

Piramal Pharma may revise FY27 performance guidance in upcoming Q2 concall

Piramal Pharma posts higher Q1 EBITDA and margin on annual basis

Piramal Pharma reports strong Q1 revenue growth on year-on-year basis

Piramal Pharma Ltd Share Price Today

Piramal Pharma Quick Links

Other Stocks

Calculators

Brokerage Calculator

Stock Average Calculator

MTF Calculator

Margin Calculator

Span Margin Calculator